HK1252870A1 - Sirp多肽組合物和使用方法 - Google Patents

Sirp多肽組合物和使用方法

Info

Publication number
HK1252870A1
HK1252870A1 HK18112214.5A HK18112214A HK1252870A1 HK 1252870 A1 HK1252870 A1 HK 1252870A1 HK 18112214 A HK18112214 A HK 18112214A HK 1252870 A1 HK1252870 A1 HK 1252870A1
Authority
HK
Hong Kong
Prior art keywords
methods
polypeptide compositions
sirp polypeptide
sirp
compositions
Prior art date
Application number
HK18112214.5A
Other languages
English (en)
Inventor
亞倫‧邁克爾‧林
羅伊‧路易斯‧莫泰
安德魯‧柯蒂斯‧克魯澤
阿希什‧芒里克
肯尼思‧S‧林
Original Assignee
起源生物醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 起源生物醫藥公司 filed Critical 起源生物醫藥公司
Publication of HK1252870A1 publication Critical patent/HK1252870A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK18112214.5A 2015-05-18 2018-09-21 Sirp多肽組合物和使用方法 HK1252870A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562163282P 2015-05-18 2015-05-18
US201562266450P 2015-12-11 2015-12-11

Publications (1)

Publication Number Publication Date
HK1252870A1 true HK1252870A1 (zh) 2019-06-06

Family

ID=57320547

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112214.5A HK1252870A1 (zh) 2015-05-18 2018-09-21 Sirp多肽組合物和使用方法

Country Status (11)

Country Link
US (3) US9845345B2 (zh)
EP (2) EP3298043B8 (zh)
JP (2) JP7064234B2 (zh)
CN (2) CN107849143B (zh)
CA (1) CA2994935A1 (zh)
DK (1) DK3298043T3 (zh)
ES (1) ES2857109T3 (zh)
HK (1) HK1252870A1 (zh)
PL (1) PL3298043T3 (zh)
PT (1) PT3298043T (zh)
WO (1) WO2016187226A1 (zh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3699189A1 (en) * 2014-08-08 2020-08-26 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
ES2857109T3 (es) 2015-05-18 2021-09-28 Ab Initio Biotherapeutics Inc Composiciones polipeptídicas de SIRP y métodos de uso
SG10201913591SA (en) 2015-10-01 2020-02-27 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
WO2018081897A1 (en) * 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
WO2018118887A1 (en) * 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
EP3939993A1 (en) * 2017-01-05 2022-01-19 KAHR Medical Ltd. A sirp1-alpha-4-1bbl fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
DK3565579T3 (da) 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
IL268346B1 (en) 2017-02-06 2024-04-01 Orionis Biosciences BV Targeted chimeric proteins and their uses
CN110300764A (zh) * 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途
JP7128195B2 (ja) 2017-02-27 2022-08-30 シャタック ラボ,インコーポレイテッド 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
SG11201906464UA (en) 2017-02-27 2019-08-27 Shattuck Labs Inc Csf1r-based chimeric proteins
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
CN108623689B (zh) * 2017-03-15 2020-10-16 宜明昂科生物医药技术(上海)有限公司 新型重组双功能融合蛋白及其制备方法和用途
EP3625259B1 (en) 2017-05-16 2024-04-17 Byondis B.V. Anti-sirpalpha antibodies
WO2018217989A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
NZ761568A (en) 2017-08-02 2022-11-25 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
KR20190037164A (ko) * 2017-09-28 2019-04-05 한국과학기술연구원 신규 암 치료용 조성물
WO2019095358A1 (zh) * 2017-11-20 2019-05-23 泰州迈博太科药业有限公司 一种靶向cd47与pd-l1的双功能融合蛋白
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3729085A1 (en) 2017-12-22 2020-10-28 Adienne S.A. Quantitative cellular method for determining the biological activity of an anti-cd26 ligand
US20230242640A1 (en) * 2018-08-22 2023-08-03 Ose Immunotherapeutics ANTI-SIRPg Compounds
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
JP2021534769A (ja) * 2018-08-31 2021-12-16 エーエルエックス オンコロジー インコーポレイテッド デコイポリペプチド
CN109293778B (zh) * 2018-11-01 2021-09-17 浙江蓝盾药业有限公司 同时抗cd70和cd47的重链抗体及其制备方法和应用
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
CA3117816A1 (en) 2018-11-26 2020-06-04 Forty Seven, Inc. Humanized antibodies against c-kit
CN116239698A (zh) * 2019-03-06 2023-06-09 江苏恒瑞医药股份有限公司 双功能融合蛋白及其医药用途
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
MX2021014178A (es) 2019-05-20 2022-01-04 Pandion Operations Inc Inmunotolerancia dirigida a la molecula de adhesion celular de adresina vascular de mucosas (madcam).
WO2020242895A1 (en) * 2019-05-24 2020-12-03 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and cd47
JP2022535286A (ja) * 2019-06-07 2022-08-05 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてcd47に結合する薬物の干渉を低減するための方法及び試薬
AU2020303986A1 (en) * 2019-06-24 2021-12-09 Amgen Inc. Inhibition of SIRP-gamma for cancer treatment
GB202409022D0 (en) 2019-09-03 2024-08-07 Myeloid Therapeutics Inc Methods and compositions for genomic integration
WO2021101966A1 (en) * 2019-11-18 2021-05-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of fibrosis with combined blockade of il-6 and immune checkpoint
IL293199A (en) 2019-11-27 2022-07-01 Alx Oncology Inc Combined therapies for cancer treatment
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
AU2021283083A1 (en) 2020-06-01 2022-12-01 ALX Oncology Inc. Combination therapies comprising a hypomethylation agent for treating cancer
WO2022010806A1 (en) 2020-07-06 2022-01-13 ALX Oncology Inc. Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
CN115885044A (zh) * 2020-09-04 2023-03-31 江苏恒瑞医药股份有限公司 SIRPγ变体及其融合蛋白
GB2617474A (en) 2020-11-04 2023-10-11 Myeloid Therapeutics Inc Engineered chimeric fusion protein compositions and methods of use thereof
EP4256336A1 (en) 2020-12-06 2023-10-11 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
KR20220138909A (ko) 2021-04-06 2022-10-14 주식회사 이뮤노로지컬디자이닝랩 Cd47에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
MX2023013259A (es) 2021-05-13 2023-11-27 Alx Oncology Inc Terapias de combinacion para el tratamiento del cancer.
US20240010701A1 (en) 2022-06-01 2024-01-11 ALX Oncology Inc. Combination therapies for treating urothelial carcinoma
KR20240034954A (ko) * 2022-09-07 2024-03-15 주식회사 시프트바이오 SIRPα 변이체에 특이적으로 결합하는 항체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
WO2010083253A2 (en) * 2009-01-14 2010-07-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
EP2524927A1 (en) * 2011-05-20 2012-11-21 Covagen AG New chymase binding compounds and medical uses thereof
WO2013056352A1 (en) * 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
EP3766511A1 (en) * 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
WO2014121093A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
ES2649165T3 (es) * 2013-02-05 2018-01-10 The Board Of Trustees Of The Leland Stanford Junior University CD47 terapias dirigidas para el tratamiento de enfermedades infecciosas
ES2857109T3 (es) 2015-05-18 2021-09-28 Ab Initio Biotherapeutics Inc Composiciones polipeptídicas de SIRP y métodos de uso

Also Published As

Publication number Publication date
EP3872086A1 (en) 2021-09-01
EP3298043A4 (en) 2018-12-19
CN114425077A (zh) 2022-05-03
EP3298043B8 (en) 2021-04-21
DK3298043T3 (da) 2021-02-15
JP7064234B2 (ja) 2022-05-10
US20200270324A1 (en) 2020-08-27
CA2994935A1 (en) 2016-11-24
EP3298043B1 (en) 2020-12-30
CN107849143A (zh) 2018-03-27
US11407801B2 (en) 2022-08-09
ES2857109T3 (es) 2021-09-28
CN107849143B (zh) 2021-12-10
JP2018524282A (ja) 2018-08-30
US20180155405A1 (en) 2018-06-07
US20160340397A1 (en) 2016-11-24
PL3298043T3 (pl) 2021-07-19
PT3298043T (pt) 2021-03-08
JP2022036957A (ja) 2022-03-08
US10774125B2 (en) 2020-09-15
EP3298043A1 (en) 2018-03-28
US9845345B2 (en) 2017-12-19
WO2016187226A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
HK1252870A1 (zh) Sirp多肽組合物和使用方法
GB2582482B (en) CASZ compositions and methods of use
HK1247238B (zh) 改造的crispr-cas9組合物和使用方法
GB2582100B (en) CAS12C Compositions and methods of use
HK1248531A1 (zh) 免疫調節組合物及其使用方法
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
PT3194564T (pt) Composições de trichoderma e métodos de utilização
HK1254960A1 (zh) 冷沉澱物組合物及其製備方法
HK1251979A1 (zh) 肽組合物和使用方法
ZA201906169B (en) Synthekine compositions and methods of use
PL3349743T3 (pl) Sposoby i kompozycje do hamowania oddziaływania dcn1-ubc12
IL257458B1 (en) dpep-1 binding compositions and methods of use
HK1252057A1 (zh) 新穎的使用方法和組合物
HK1250345A1 (zh) 包含15-氧代-epa或15-氧代-dgla的組合物及其製備和使用方法
HK1247136A1 (zh) 包含15-hepe的組合物和其使用方法
GB201511799D0 (en) Composition and methods of treatment
SG11201705490QA (en) Mercaptanized vinylnorbornene compositions and methods of making same
HK1248527A1 (zh) 牙科組合物和使用方法
PL3445730T3 (pl) Makrokompozyty i kompozycje z kamienia i szkła oraz sposoby wytwarzania
IL261794A (en) Preparations and methods for using them